BSEInsider Trading / SAST28 Sept 2026 · 28 Sept 2026, 02:17 pm
Closure of Trading Window
Suven Life Sciences Ltd · 530239
✦ AI Summary
Suven Life Sciences Ltd has announced the closure of its trading window for all designated persons and their immediate relatives, effective from 01 October 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended 30 September 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst5/10
Governance Concern2/10
Regulatory Risk2/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Suven Life Sciences Ltd - 530239 - Closure of Trading Window
Attachments (1)
📄pdf
Download →
ba3b80bc-531e-4594-9f69-9136dd4c2a40.pdf
View document text
CSD/BSE&NSE/TW/2026-27
Date: 28th September, 2026
To To
The General Manager The Manager
Department of Corporate Services Listing Department
BSE Limited National Stock Exchange of India Limited
25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex
Dalal Street, Mumbai - 400 001 Bandra (E), Mumbai – 400 051
Scrip Code: 530239 Scrip Symbol: SUVEN
Dear Sir/Madam,
Sub: Intimation of Closure of Trading Window
Pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading)
Regulations, 2015 and the Company’s Code of Conduct to regulate, monitor and report
trading of designated persons, the ‘Trading Window’ for dealing in securities of the
Company for all the designated persons and their immediate relatives, Connected
Persons (including their relatives) as covered under the said code shall remain close
with effect from 01 October, 2026, till the expiry of 48 hours after the declaration of
unaudited Financial Results for the quarter and half year ended 30 September, 2026.
Accordingly, all Designated Persons of the Company are being advised not to trade in
the securities of the Company during the aforesaid period of closure of the Trading
Window.
Please note that the date of Board Meeting for consideration and approval of
unaudited financial results of the Company for quarter and half year ended September
30, 2026, shall be communicated in due course.
This is for your information and records.
Thanking you,
Yours faithfully,
For Suven Life Sciences Limited
K. Sangeetha Laxmi
Company Secretary & Compliance Officer
Suven Life Sciences Limited
Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7
Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com